Wockhardt share price gains 14% on DCGI approval for 2 new antibiotics
Wockhardt share price gained 14 percent intraday on January 16 after the pharma company received Indian regulatory approval for its two new antibiotics.
The Drug Controller General of India (DCGI) approved EMROK (IV) and EMROK 0 (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections, and concurrent bacteraemia.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.